Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Melanoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 44Paclitaxel 21Radiotherapy 20Brachytherapy 19Carboplatin 18Bevacizumab 7Drug Therapy 6camrelizumab 5toripalimab 4nimotuzumab 4Radiation 4Neoadjuvant Therapy 4Gemcitabine 4tislelizumab 3sintilimab 3pembrolizumab 3apatinib 3Vaccines 3TP protocol 3Surgical Procedures, Operative 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3nedaplatin 2fludarabine 2endostar protein 2anlotinib 2Topotecan 2Surveys and Questionnaires 2Sentinel Lymph Node Biopsy 2Radiotherapy, Intensity-Modulated 2Mindfulness 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Uterine Cervical Neoplasms × famitinib × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡